ATE381345T1 - Alpha-emittierende konstrukte sowie deren verwendung - Google Patents

Alpha-emittierende konstrukte sowie deren verwendung

Info

Publication number
ATE381345T1
ATE381345T1 AT99940789T AT99940789T ATE381345T1 AT E381345 T1 ATE381345 T1 AT E381345T1 AT 99940789 T AT99940789 T AT 99940789T AT 99940789 T AT99940789 T AT 99940789T AT E381345 T1 ATE381345 T1 AT E381345T1
Authority
AT
Austria
Prior art keywords
cells
alpha
constructs
emitting
emitting constructs
Prior art date
Application number
AT99940789T
Other languages
English (en)
Inventor
David Scheinberg
Dangshe Ma
Michael Mcdevitt
George Sgouros
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE381345T1 publication Critical patent/ATE381345T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Revetment (AREA)
AT99940789T 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung ATE381345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8677298P 1998-05-26 1998-05-26

Publications (1)

Publication Number Publication Date
ATE381345T1 true ATE381345T1 (de) 2008-01-15

Family

ID=22200805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940789T ATE381345T1 (de) 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung

Country Status (7)

Country Link
EP (1) EP1091757B1 (de)
JP (1) JP5064608B2 (de)
AT (1) ATE381345T1 (de)
CA (1) CA2333125C (de)
DE (1) DE69937797D1 (de)
ES (1) ES2299256T3 (de)
WO (1) WO1999061097A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
EP2727606A3 (de) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
DE69033631T2 (de) * 1989-12-14 2001-05-17 Sloan Kettering Inst Cancer Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
DK0627940T3 (da) * 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
WO1999061097A3 (en) 2000-02-03
ES2299256T3 (es) 2008-05-16
EP1091757A4 (de) 2002-08-07
WO1999061097A2 (en) 1999-12-02
JP5064608B2 (ja) 2012-10-31
CA2333125C (en) 2009-12-15
JP2002516297A (ja) 2002-06-04
DE69937797D1 (de) 2008-01-31
EP1091757A2 (de) 2001-04-18
CA2333125A1 (en) 1999-12-02
EP1091757B1 (de) 2007-12-19
WO1999061097A9 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
MY121548A (en) Compounds and methods for the treatment of cancer
DE60239394D1 (de) Onkolytische virustherapie
ATE263252T1 (de) Erzielbare vektorenpartikel
ATE33556T1 (de) Adenosinderivate enthaltende pharmazeutische zusammensetzung fuer behandlung von tumoren.
NO870772D0 (no) Vevplasminogenaktivator for normale humane tykktarmceller.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
AR007493A1 (es) Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica
Corn et al. Stereotactic radiosurgery and radiotherapy: new developments and new directions
CA2385369A1 (en) Radiation source for endovascular radiation treatment in form of a wire
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE69937797D1 (de) Alpha-emittierende konstrukte sowie deren verwendung
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
AU6751294A (en) Protection from shock subsequent to injury by double-standard RNAs
Beer et al. Reassessment of the differential effects of ultraviolet and ionizing radiation on HIV promoter: the use of cell survival as the basis for comparisons
ES2182983T3 (es) Formulaciones para la liberacion de peptidos.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
DK0697875T3 (da) Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties